Sp388
PERIANAL AND INTRAABDOMINAL FISTULAS IN CROHN’S: ROLE OF MEDICATIONS, DIET, STEM CELLS, AND SURGERY
Date
May 19, 2024
Explore related products in the following collection:
Presenter
Cleveland Clinic
Tracks
Related Products
RISANKIZUMAB VERSUS USTEKINUMAB FOR THE ACHIEVEMENT OF CLINICAL REMISSION AND REDUCTION IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE TRIAL
Improved clinical outcomes and normalization of objective markers of inflammation are important treatment targets per STRIDE-II consensus for patients (pts) with Crohn’s disease (CD)…
ORAL SMALL MOLECULES ARE NOT ASSOCIATED WITH INCREASED CANCER RATES IN IBD PATIENTS
Oral small molecules (OSM) have demonstrated effectiveness in treating IBD. Certain studies have associated certain OSM with an increased cancer risk. We aimed to assess the cancer risk in IBD patients treated with OSM…
